Daily Brief Archive: July 10, 2026 — U.S. & Hong Kong Stock Analysis

Free preview

U.S. Markets

S&P +0.8%, Nasdaq +1.3% — chips led the tape right through the Iran escalation
SMH +2.5% with MU +4.5%, AMD +5.7%, SNDK +7.6%; falling crude defused the inflation alarm
SK Hynix's IPO was 7x oversubscribed at $149; it debuts on Nasdaq today as SKHY
IONS -24% on the failed AstraZeneca-partnered ATTR-CM Phase 3; BBIO +15% as the rival winner
COST -4.2%: June comps of +8.8% missed, and a 42x multiple has no room for 'merely in line'

Hong Kong

HSI +0.57% in a structural tape: property, materials and brokers strong, big tech soft
The memory chain surged into the SKHY debut — GigaDevice ripped 22% in a day
WuXi Biologics +5.6%: UBS lifted its target to HK$51.10 amid buybacks and upbeat CRO pre-announcements
MiniMax slid another 7.5% into oversold territory — unlock supply still hasn't cleared
Alibaba extended gains at the highs as the China AI re-rating entered day three

Today's Watchlist

SKHY's debut is the memory sector's pricing ceremony — Micron's direct comp has arrived
Today's action: re-opened the RIVN long (offering overhang cleared); all other 46 positions held
Delta reports premarket today — summer fares are the consumer thermometer
Earnings season nears: SYF 7/21, TSLA 7/22 — volatility ratchets up from here
The Iran conflict is escalating yet markets are desensitizing — falling crude is the macro signal that matters

Deep Dives (2 names)

Long

9988 阿里巴巴 · Internet & E-commerce

Open PositionWatchlist

+11.97%07-02“It kept climbing on a day HK tech broadly slipped — a re-rating's hardest evidence isn't magnitude but independence. After an 18.6% week the extension is maxed; stop up to HK$105 and let the market decide which page this story ends on”

HK$112

+3.70%

Score8/10RSI(14) 57.0Weekly +18.6%Open P&L ~+9% (opened 7/8)Tape character Re-rating day three, alone strong as tech slipped

Technicals — Up 3.7% to HK$112.00, +18.6% on the week, leading against the tape as HK tech slipped. RSI 57 has room and the 50-day (HK$117.50) is first resistance; but an 11% extension over the 20-day (HK$101.20) means retest pressure is accumulating.

Fundamentals — The three-day re-rating rests on unchanged pillars: Q1 e-commerce profit repair with flash-sale losses shrinking faster than expected, first position on the H200 access list, and banks collectively lifting China AI valuation frameworks. After +18.6% in a week, the fastest leg of the re-rating is done — earnings must take the baton.

News — In Friday's structural tape with tech broadly soft, its +3.7% shows the bid is active allocation, not sector beta. The southbound-versus-foreign tug-of-war over pricing power is the next act.

Short-term · 1–3 weeks

Long Bullish

Holding (~+9% in three days): strength independent of the sector confirms the re-rating isn't done. Stop raised from HK$100 to HK$105 to bank half the gain, with the next raise past the 50-day (HK$117.50).

Entry Hold; latecomers wait for a HK$103–106 retest rather than chasing an 11% extensionStop HK$105Target HK$130

Long-term · months+

Accumulate

The cloud-plus-AI second curve just got a tangible compute catalyst, with stabilized e-commerce profits as the cushion; still 22% below the 200-day, the re-rating runway isn't spent.

H200 access policy reversals
Technical give-back after an 18.6% week
A reignited subsidy war eroding the profit repair

Signal BacktestCumulative +11.97%price itself +19.02%0/1 closed trades wonprofitable since 07-09

07-02LongHK$94.5 → closed HK$94.107-04-0.42%
07-08LongHK$99.6 → open → HK$112+12.45%

Community Voices

雪球 · From 'selling the bounce at 110' to 'this time is different' took exactly three days — stops don't change conviction; people without stops doOriginal ↗

Institutional Views

华尔街共识 · 34 analysts, average target HK$186.40 (+66% vs. spot), 1.16 — strong-buy territory

Long

2269 药明生物 · CXO

Open Position

New today“Up 37% in a month and still getting UBS target hikes plus HK$100M of company buybacks — a CXO spring is built from orders, not slogans. Positions that grind from red to green are the hardest to hold; the stop raised to HK$34 will manage your hands for you”

HK$39.14

+5.61%

Score8/10RSI(14) 68.7Day move +5.6%1-month +37.4%Institutional move UBS target raised to HK$51.10

Technicals — Up 5.6% to HK$39.14 — a second high-volume candle in the acceleration leg, +37.4% on the month. RSI at 68.7 approaches overbought, but early-trend overbought is proof of strength; HK$42 (the 52-week-high zone) is the next test, with the 20-day (HK$33.60) far below.

Fundamentals — UBS raised FY2027–29 revenue forecasts with its target going HK$49.30→51.10; the company bought back 2.72M shares for nearly HK$100M on 7/7. With WuXi AppTec's upbeat pre-announcement lighting up the CRO complex, the biologics-outsourcing utilization recovery is being validated by orders.

News — CXO has become one of the strong seams in HK's structural tape — pre-announcement beats, buybacks and foreign upgrades resonating. This position's repair from -3.3% to roughly +9% is a textbook case for patience.

Short-term · 1–3 weeks

Long Bullish

Holding (~+9%): acceleration leg, institutional upgrades and buybacks in triple support. Stop raised from HK$32.50 to HK$34 (tight, just above the 20-day); at RSI near 70, no adds — and no preemptive trimming either.

Entry Hold; a low-volume dip to HK$36–37 is the add-watch zoneStop HK$34Target HK$45

Long-term · months+

Accumulate

The twin inflection of biologics-outsourcing penetration and utilization is order-verified, the darkest geopolitical hour has passed, and the multiple still sits in the lower half of its historical range.

US biosecure-legislation risk reigniting
Mean-reversion pressure after a 37% month
Order conversion and capacity ramp cadence

Community Voices

雪球 · Two weeks ago the board debated whether CXO was a value trap; today they're modeling 2028 capacity — research writes itself fast in a bull tapeOriginal ↗

Institutional Views

华尔街共识 · 17 analysts, average target HK$50.60 (+29% vs. spot), 1.15 — strong-buy territory
瑞银 · Raised FY2027–29 revenue forecasts; DCF-based target lifted to HK$51.10Source ↗

Rapid Scan (8 names)

Ticker	Close	Change	Score	Direction	One-line take
700 HK	HK$465.8	-0.81%	7	Long	Down 0.8%, the first give-back after eight green days — normal breathing on a soft-tech day; stop stays HK$450, holding
1211 HK	HK$83.9	+1.51%	7	Long	Up 1.5%, grinding higher along the 20-day on the export re-rating; stop HK$78, holding
1810 HK	HK$25.48	+1.92%	7	Long	Up 1.9%, +10.9% on the week — a strong branch of the tech repair; the 50-day (HK$27.40) is the next test
3690 HK	HK$78.35	-0.19%	6	Long	Down 0.2% in a high-level pause after a +9.8% week; the LongCat story still fermenting — holding
1801 HK	HK$90.5	+4.81%	7	Long	Up 4.8%, attacking in resonance with the CXO and biotech complex, +25.7% on the month; gains widening, holding
2899 HK	HK$29.84	+1.43%	6	Long	Up 1.4% in repair mode — gold steadied and copper carries the case; safe distance to the HK$28 stop restored, holding
2259 HK	HK$99.2	-0.50%	5	Long	Down 0.5% in weak consolidation with gold still soft; the HK$95 hard stop stands a third day — a break means out, no debate
5 HK	HK$153.7	+0.92%	7	Long	Up 0.9% to HK$153.70, 1% from a 52-week high; the high-yield mega-bank's trend has zero noise — holding